Drugs / PDC*lung01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03970746 | Sep 2019 → Jul 2024 overdue | non-small cell lung carcinoma | PDC*line Pharma SAS | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDC*lung01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970746 ↗ |
| Modality | Vaccine | “therapeutic cancer vaccine” NCT03970746 ↗ |
| Route | Intravenous | “administered successively by subcutaneous and then by intravenous route” NCT03970746 ↗ |
| Route | Subcutaneous | “administered successively by subcutaneous and then by intravenous route” NCT03970746 ↗ |